Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Dow
McKesson
Mallinckrodt
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

ELIDEL Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Elidel, and when can generic versions of Elidel launch?

Elidel is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in ELIDEL is pimecrolimus. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pimecrolimus profile page.

Drug patent expirations by year for ELIDEL
Drug Prices for ELIDEL

See drug prices for ELIDEL

Recent Clinical Trials for ELIDEL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St Joseph University, Beirut, LebanonPhase 2/Phase 3
PfizerPhase 4
Glenmark Pharmaceuticals Ltd. IndiaPhase 3

See all ELIDEL clinical trials

Pharmacology for ELIDEL
Synonyms for ELIDEL
071P320
137071-32-0
33-epi-Chloro-33-desoxyascomycin
7KYV510875
AB01566841_01
ABP000224
AK104470
AKOS015895946
ASM-981
ASM-998
B1817
BRD-K92107055-001-01-9
C43H68ClNO11
CHEBI:135888
CHEMBL1200686
CS-2691
D05480
DB00337
Elidel (TN)
EX-A2138
GTPL6783
HY-13723
I06-1252
MolPort-003-666-749
NCGC00167506-01
Pimecrolimus
Pimecrolimus (JAN/USAN/INN)
Pimecrolimus [USAN:INN:BAN]
Pimecrolimus, >=97% (HPLC)
Pimecrolimus(Elidel)
Pimecrolimus/
Pimecrolimusum
Q-201579
s5004
SCHEMBL3000675
SCHEMBL438880
SDZ ASM 981
SDZ-ASM 981
SDZ-ASM-981
ST24048917
UNII-7KYV510875
X7261
ZINC85536990

US Patents and Regulatory Information for ELIDEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ELIDEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001   Start Trial   Start Trial
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001   Start Trial   Start Trial
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Baxter
Mallinckrodt
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.